Pfizer is a big company with a diverse portfolio, but it hasn’t really been noted for its presence in the oncology market. The majority of its successful drugs are in primary care and heart medicine, like Lipitor (atorvastatin) for cholesterol, Lyrica (pregabalin) for neuropathic pain and fibromyalgia, Zithromax (azithromycin), an antibiotic, and Viagra (sildenafil) for erectile dysfunction.
辉瑞（Pfizer）是一家拥有多元化产品组合的大公司，但其在肿瘤市场的地位并未引起人们的注意。其大部分成功的药物是初级保健和心脏医学，如胆固醇的利普妥（阿托伐他汀），神经病理性疼痛和纤维肌痛的利卡卡（普瑞巴林），抗生素的 Zithrax （阿奇霉素），勃起功能障碍的伟哥（西地那非）。
But now, Pfizer offers 17 drugs to treat cancer, with four approved in the U.S. in 2017. The oncology portfolio, according to EvaluatePharma, is projected to bring in $8.3 billion in sales in 2019. For the first time, cancer drugs are expected to sell more than the cardiac and primary-care medicines.
但现在，辉瑞（Pfizer）提供了17种治疗癌症的药物，2017年在美国批准了4种。根据 EvaluatePharma 的数据，肿瘤产品组合预计将在2019年带来83亿美元的销售额。癌症药物预计将首次超过心脏和初级保健药物。
“At Pfizer, oncology is one of the core components of the organization—going from an almost afterthought,” Andy Schmeltz, global president of Pfizer Oncology, told the Wall Street Journal.
辉瑞肿瘤学全球总裁安迪•施梅尔茨( Andy Schmeltz )在《华尔街日报》上表示：“在辉瑞（Pfizer），当我们想到让肿瘤学成为核心组成部分之一时，已经很晚了。”
WSJ indicates that marketing executives in the biopharma industry like oncology because promoting these drugs to oncologists and hospitals takes a smaller sales force than to market cholesterol and hypertension drugs to primary care physicians.
华尔街日报指出，生物制药行业的营销主管就像肿瘤学一样，因为向肿瘤学家和医院推销这些药物比向初级保健医生推销胆固醇和高血压药物简单得多。
And according to EvaluatePharma, oncology drug sales are projected to hit $138 billion globally this year with an 11-percent growth rate in 2019. They’re fairly pricey drugs as well, with a typical cancer drug having a list price of $100,000.
据 EvaluatePharma 预测，今年全球肿瘤药物销售额将达到1380亿美元，2019年将增长11%，当然这些肿瘤药物也十分昂贵，比如，一种典型的抗癌药物定价10万美元。
本文未完，阅读全文请访问www.investank.com
